The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Inclusion Criteria:

• Participants in the advanced melanoma cohort

  • Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database

• Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off)

• Participants ≥18 years old on index date

• Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period

Exclusion Criteria:

• Participants with diagnosis of other primary cancers prior to the index date
• Participants receiving medication in a clinical trial at any time prior to, on or after index date

The study population will include adults identified from the Flatiron database that have been diagnosed with advanced melanoma and who have initiated treatment with either Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy in the real-world clinical settings